The diagnosis and treatment of nail disorders: Systemic antifungal therapy

Dermatologic Therapy

Volumn 15, Issue 2, 2002, Pages 78-88

  Mackay Wiggan, Julian ^a   Elewski, Bonnie E ^a   Scher, Richard K ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Onychomycosis; Systemic antifungals; Therapy; Tinea unguium

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN; FLUCONAZOLE; GRISEOFULVIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; ITRACONAZOLE; KETOCONAZOLE; MONOAMINE OXIDASE B INHIBITOR; NARCOTIC AGENT; NEUROLEPTIC AGENT; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TERBINAFINE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

ANTIFUNGAL ACTIVITY; DERMATOLOGY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; MEDICAL SPECIALIST; NAIL DISEASE; REVIEW;

EID: 0036330817     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2002.01514.x     Document Type: Review

References (75)

1. Prevalence of dermatophyte onychomycosis in the United Kingdom: Results of an omnibus survey
2. Prevalence of dermatophyte onychomycosis in Spain: A cross sectional study
3. The prevalence of onychomycosis in Finland
4. Onychomycosis
5. The prevalence and management of onychomycosis in diabetic patients
6. Onychomycosis in children: Prevalence and management
7. Fungal diseases with cutaneous involvement
8. Onychomycosis, tinea pedis and tinea manum caused by non-dermatophyte filamentous fungi
9. A US epidemiologic survey of superficial fungal diseases
10. Onychomycosis
11. 6Cl a metabolic product of Penicillium griseofulvin
12. Antifungal agents: An overview. Part 1
13. Systemic antifungal agents
14. Onychomycosis in the elderly
15. Onychomycosis: Current treatment and future challenges
16. Heterocyclic spironaphthalenones. Part 1: Synthesis and reactions of some spiro [(1 H-naphthalenone)]-l,3,-piperidines
17. Terbinafine mode of action and properties of the squalene epoxidase inhibition
18. Investigation of terbinafine as a CYP 2D6 inhibitor in vivo
19. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine
20. Nail incorporation kinetics of terbinafine in onychomycosis patients
21. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks
22. Clinical pharmacokinetics of terbinafine (Lamisil)
23. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: A new approach
24. Open randomized comparison of itraconazole versus terbinafine in onychomycosis
25. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection
26. A 12 week treatment for dermatophyte toe onychomycosis: Terbinafine 250 mg/day vs. itraconazole 200 mg/day - A double blind comparative trial
27. Onychomycosis treated with a short course of oral terbinafine
28. Short term treatment of dermatophyte onychomycosis with terbinafine
29. Oral terbinafine in toenail dermatophytosis
30. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy
31. A randomized treatment duration finding study of terbinafine in onychomycosis
32. Terbinafine in onychomycosis of the toenail: A novel treatment protocol
33. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
34. Itraconazole compared to terbinafine in superficial fungal infections: From petri dish to patient
35. A study to compare the efficacy of Lamisil® (terbinafine) and Diflucan® (fluconazole) in patients with onychomycosis
36. Long-term post treatment follow-up of onychomycosis treated with terbinafine: A multicenter trial
37. Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy
38. Itraconazole versus terbinafine (Lamisil®). Which is better for the treatment of onychomycosis?
39. The prevalence of onychomycosis in children and treatment strategies
40. Overview of the use of terbinafine (Lamisil®) in children
41. Management of onychomycosis in children
42. Treatment of childhood dermatophyte infections with oral terbinafine
43. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses
44. Levels of fluconazole in serum, stratum corneum, epidermis (without stratum corneum) and eccrine sweat
45. Pharmacokinetic evaluation of fluconazole in skin and nails
46. Pharmacokinetics of three doses of once-weekly fluconazole (150, 300 and 400 mg) in the management of distal subungual onychomycosis of the toenail
47. An open label, noncomparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis
48. Fluconazole in the treatment of onychomycosis caused by dermatophytes
49. Fluconazole in the treatment of severe onychomycosis
50. A placebo controlled, randomized, double-blind trial of once-weekly fluconazole (150mg, 300mg or 450mg) in the treatment of distal subungual onychomycosis of the toenail
51. A comparison of the efficacy of oral griseofulvin, fluconazole and terbinafine in the treatment of onychomycosis
52. Once weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail
53. Pharmacokinetics of oral antifungal agents
54. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis
55. The new oral antifungal agents for onychomycosis of the toenails
56. Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis
57. Double blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis
58. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail
59. The use of itraconazole in onychomycosis
60. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail
61. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toenail onychomycosis
62. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: A 6-week pilot study
63. A multicenter, placebo controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail
64. Small-dose itraconazole pulse therapy in the treatment of onychomycosis
65. Itraconazole pulse therapy is effective in the treatment of onychomycosis: A pharmacokinetic/pharmacodynamic and clinical evaluation
66. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis
67. Itraconazole in onychomycosis; intermittent dose schedule
68. The safety and efficacy of intermittent therapy with itraconazole for finger and toenail onychomycosis: A multicenter trial
69. An intermittent 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological patients
70. Treatment efficacy and safety of 1-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population